Spironolactone for HFpEF & HFmrEF: Does it Help?

The search for effective treatments for heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) – a condition affecting millions and proving stubbornly resistant to improvement – has hit another roadblock. Results from the SPIRIT-HF trial, presented at ACC.26, demonstrate that spironolactone, a commonly used aldosterone blocker, offered no significant benefit in reducing heart failure hospitalizations or cardiovascular death compared to placebo. This finding is particularly disheartening given the limited therapeutic options currently available for this patient population.

HFpEF/HFmrEF represents a significant clinical challenge. Unlike heart failure with reduced ejection fraction (HFrEF), which has seen substantial advances with therapies like SGLT2 inhibitors and ARNI’s, effective treatments for HFpEF/HFmrEF have remained elusive. The underlying pathophysiology of HFpEF is complex and multifactorial, involving inflammation, myocardial stiffness, and endothelial dysfunction, making it a difficult target for single-drug interventions. Spironolactone was hypothesized to improve outcomes by blocking aldosterone, a hormone that can contribute to these processes. Previous, smaller studies had hinted at potential benefits, fueling the investigation in a larger, more definitive trial like SPIRIT-HF.

The SPIRIT-HF trial, conducted across four European countries with nearly 730 patients, aimed to address this gap. However, the results were unequivocal: spironolactone did not demonstrate a statistically significant improvement in the primary endpoint. Furthermore, the increased incidence of adverse events – particularly hospitalizations – is a critical finding. Dr. Frank Edelmann, the study’s lead author, rightly emphasized the need for careful consideration of potential side effects, including renal function and potassium levels, when using spironolactone in this population. The meta-analysis combining SPIRIT-HF with TOPCAT data further reinforces the lack of efficacy.

The Forward Look: The negative results of SPIRIT-HF don’t necessarily signal the end of aldosterone blockade research in HFpEF/HFmrEF, but they do necessitate a recalibration of strategy. The focus is likely to shift towards identifying patient subgroups who *might* benefit from spironolactone, perhaps those with specific biomarkers or comorbidities. More importantly, the failure of this single-agent approach underscores the need for combination therapies. We can expect to see increased investigation into combining spironolactone with newer agents like SGLT2 inhibitors, which have shown promise in HFpEF, to see if a synergistic effect can be achieved. The ongoing registry study mentioned by Dr. Edelmann will be crucial, as will future trials exploring alternative aldosterone-modulating strategies. The field is also increasingly focused on addressing the underlying mechanisms of HFpEF, potentially leading to the development of entirely new therapeutic targets. For now, clinicians will need to carefully weigh the potential risks and benefits of spironolactone, prioritizing patient safety and closely monitoring for adverse events.